Orthofix Medical Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022; comparisons are with the three months ended March 31, 2021. Amounts are U.S. dollars unless noted. Orthofix is a global medical-device company focused on spine and orthopedics, with products distributed in more than 60 countries.
Financial performance
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Net sales | $106.4 million | $105.6 million |
| Gross profit / margin | $78.1 million / 73.4% | $79.7 million / 75.5% |
| Operating loss | $3.1 million | $2.9 million |
| Net loss | $4.5 million | $5.8 million |
| Diluted loss per share | $0.22 | $0.30 |
| Operating cash flow | $(7.7) million | $2.4 million |
| Capital expenditures | $5.7 million | $4.8 million |
| Free cash flow (non-GAAP) | $(13.4) million | $(2.3) million |
Q1 2022 EBITDA, a non-GAAP measure, was $3.5 million versus $1.8 million. Segment EBITDA was $15.9 million for Global Spine, $(3.1) million for Global Orthopedics, and $(9.3) million for Corporate.
Liquidity and financial position
Cash and cash equivalents were $71.9 million at March 31, 2022, down from $87.8 million at December 31, 2021. Total current assets were $255.1 million and current liabilities were $88.2 million. Orthofix had no borrowings under its secured revolving credit facility or its €5.5 million Italian credit lines and reported compliance with required covenants. Finance lease liabilities totaled $20.3 million; total lease liabilities, including operating leases, were $27.5 million.
Material changes and management commentary
- Sales increased 0.8% reported and 2.0% at constant currency. Global Spine grew 0.4% and Global Orthopedics grew 2.2% reported, or 7.2% at constant currency.
- Bone Growth Therapies sales fell 2.3%, which management attributed partly to hospital restrictions and staff shortages affecting complex procedures and access to accounts. Spinal Implants grew 3.6% and Biologics 2.9%. Orthopedics growth reflected international recovery and distributor orders, partly offset by currency effects.
- Gross margin declined 2.1 percentage points. Management cited higher component costs from supply-chain disruption, unfavorable sales mix, and higher indirect operating expenses.
- Sales and marketing expense rose 6.6%, and general and administrative expense rose 17.5%; management cited increased staffing, marketing, travel, professional fees, share-based compensation, legal settlements, strategic investments, and medical benefits.
- Operating cash flow declined by $10.2 million year over year, with working-capital changes—particularly inventory—among the cited factors. Inventory rose to $88.8 million from $83.0 million at year-end.
Outlook, risks, contingencies, and unusual items
- The filing provides no specific quantitative revenue or earnings guidance. Management noted that Q1 results are not necessarily indicative of full-year results.
- A $5.5 million decrease in the estimated fair value of Spinal Kinetics contingent consideration was recorded as a reduction of acquisition-related expense, producing a net $3.5 million credit in that expense line for the quarter. The remaining milestone has a stated payment of $30 million if achieved, or no payment if it is not achieved within the required timeline; its estimated fair value was $11.7 million. Management expected achievement within the next 12 months, while the valuation table identifies 2023 as the projected achievement year.
- The Italian Medical Device Payback liability was accrued at $5.4 million. The law’s implementation remains uncertain, and the eventual liability could be higher or lower.
- The remaining CARES Act advance-payment contract liability was $1.4 million. Medicare recoupment increased to 50% of payments beginning in March 2022 and was described as continuing for six months.
- Management identified global supply-chain and logistics disruption as a risk, including possible indirect effects from the Russia-Ukraine conflict and related sanctions. It reported no meaningful direct business in Russia and could not predict broader consequences.
- A related-party technology assignment and royalty agreement provides for consideration of up to $10 million to a company partly owned and controlled by the CEO’s wife; none of the contingent consideration had been paid by March 31, 2022.
- The FDA granted PMA approval for the AccelStim bone growth stimulator for fresh fracture care, and Orthofix received FDA clearance for the TrueLok Evo Ring Fixation system.
Key facts for investors to verify
- Whether sales growth and product launches can offset pressure on Bone Growth Therapies and gross margin.
- Inventory levels, supply costs, and working-capital trends given negative operating and free cash flow.
- The timing and probability of the remaining Spinal Kinetics milestone, including the difference between its $11.7 million estimated fair value and its $30 million contractual payment.
- Potential final exposure under the Italian Medical Device Payback measure and the pace of CARES Act recoupments.
- Any subsequent updates to the related-party agreement, supply-chain risks, or the company’s outlook; no numerical guidance is provided in this filing.